CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
CAR T-cell therapy efficacy in solid tumors is limited by inadequate T-cell migration and/or persistence in tumour microenvironment. Here, the authors show that the activity of tumour-antigen specific CAR T cells, in multiple preclinical mouse models, can be enhanced by co-expression of two IL-8 rec...
Guardado en:
Autores principales: | Linchun Jin, Haipeng Tao, Aida Karachi, Yu Long, Alicia Y. Hou, Meng Na, Kyle A. Dyson, Adam J. Grippin, Loic P. Deleyrolle, Wang Zhang, Didier A. Rajon, Qiong J. Wang, James C. Yang, Jesse L. Kresak, Elias J. Sayour, Maryam Rahman, Frank J. Bova, Zhiguo Lin, Duane A. Mitchell, Jianping Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/de9a908e5e6e46b0b45bc79a9225470e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Type 1 diabetes patients increase CXCR4+ and CXCR7+ haematopoietic and endothelial progenitor cells with exercise, but the response is attenuated
por: Guy S. Taylor, et al.
Publicado: (2021) -
CXCR3 chemokine receptor ligands in sarcoidosis
por: N. M. Lazareva, et al.
Publicado: (2021) -
CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells
por: Mario Bunse, et al.
Publicado: (2021) -
Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients.
por: Malgorzata Walentowicz-Sadlecka, et al.
Publicado: (2014) -
ROLE OF CXCR3 CHEMOKINE RECEPTOR AND ITS LIGANDS IN CERTAIN DISEASES
por: N. A. Arsentieva, et al.
Publicado: (2019)